NCT01612377终止2 期
A Phase II, Double-blind, Controlled, Multi-center, Randomized, Long Term Safety Trial of z102 and Prednisone (5 mg or 7.5 mg) in Patients With Moderate to Severe Rheumatoid Arthritis
Zalicus1 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2012年3月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- Difference in incidence rates of adverse events between treament groups
研究概览
简要总结
This study will compare an experimental drug called Z102 (combination of prednisolone and dipyridamole, against prednisone 5mg and prednisone 7.5mg in patients with moderate to severe Rheumatoid Arthritis for a period of 52 weeks.
详细描述
This is a long-term Phase II safety study of approximately 52 weeks in duration. Eligible patients will have completed at least 6 weeks of Protocol Z102-008 and will have met all inclusion and exclusion criteria for this study.
All patients will be up-titrated on Z102 over 3 weeks or will receive prednisone 5.0 mg or 7.5 mg:
Primary objectives:
- Adverse events (AEs)
- Vital signs
- Clinical laboratory and clinical chemistry evaluations
Secondary objectives:
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have completed all 12 weeks of Protocol Z102-008 or discontinued after participating in at least 6 weeks of the randomized withdrawal portion of Z102-008 for acceptable reasons
- •Have met all inclusion/exclusion criteria for enrollment into Protocol Z102-008
- •Have been on DMARD therapy for at least 90 days and have been on a stable DMARD dose without dosage adjustment or modification for 6 weeks prior to enrollment into Protocol Z102-008, and be able to maintain the same dose of conventional DMARD therapy during Protocol Z102-009 participation
排除标准
- •Did not complete 6 weeks of the double-blind section of Protocol Z102-008, or was discontinued from Protocol Z102-008 for reasons of an AE, protocol violation, or non-compliance
- •Active cardiovascular disease, unless well controlled by appropriate treatment, for a minimum of 3 months prior to screening for enrollment into Protocol Z102-008
- •Currently taking aspirin for reasons other than for cardiovascular prophylaxis or their total daily dose is greater than 325 mg
- •Taking oral steroids at a daily prednisone dose, or the equivalent, of >10 mg/day within the past 2 weeks
- •Intraarticular, intramuscular, or intravenous glucocorticoids must not have been given at least 6 weeks prior to entering study Protocol Z102-008 or Protocol Z102-009, at any time during the study, or be anticipated to be given at any time during the study
- •The need to continue the use of one or multiple NSAIDs at the same time, or use acetaminophen on a chronic basis
- •All opiate use is prohibited.
- •Use of any other medications or herbs or non-pharmacological treatments (e.g., acupuncture) used for the treatment of pain is prohibited
- •Has, or has had, any active severe infections or recent invasive surgical procedures within 30 days of Protocol Z102-008 or Protocol Z102-009 initiation
- •HIV, hepatitis B, or hepatitis C infection
- •Has undergone administration of any investigational drug within 30 days of study
- •All biologic agents are excluded for 90 days prior to Screening and during the conduct of Protocol Z102-008, and Protocol Z102-009
- •Has undergone administration of rituximab or any B-cell depleting investigational drugs within 6 months of Protocol Z102-008 Screening or Protocol Z102-009 initiation, or at any time during participation in study Protocol Z102-008
- •Has a history of hypersensitivity reaction to glucocorticoids and/or dipyridamole
- •Known or suspected history of alcohol or drug abuse within 2 years prior to Screening for Protocol Z102-008
- •Has any other medical condition which may interfere with the conduct of this study in the opinion of the investigator
研究组 & 干预措施
prednisolone-dipyridamole
Experimental
干预措施: Prednisolone-Dipyridamole (Drug)
prednisone 5mg
Active Comparator
干预措施: prednisone (Drug)
prednisone 7.5mg
Active Comparator
干预措施: prednisone (Drug)
结局指标
主要结局
Difference in incidence rates of adverse events between treament groups
时间窗: 12 months
次要结局
- Joint imaging(12 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Phase II Trial Comparing Z-102 With Placebo In Patients With Moderate To Severe Rheumatoid ArthritisRheumatoid ArthritisNCT01369745Zalicus294
已完成
2 期
PSD502 in Subjects With Premature EjaculationPremature EjaculationNCT03578783Plethora Solutions Ltd121
已完成
2 期
Efficacy of Methylprednisolone for Hantavirus Cardiopulmonary SyndromeHantavirus InfectionsNCT00128180University of New Mexico66
已完成
2 期
An Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic InsomniaPrimary InsomniaSecondary InsomniaNCT00784875Eli Lilly and Company643
招募中
2 期
A Study of SDX-7320 in Combination With Eribulin for People With Breast CancerMetastatic Triple-Negative Breast CancerBreast CancerNCT05570253Memorial Sloan Kettering Cancer Center55